
|Videos|June 30, 2021
The Future of Pharmaceuticals and the FDA Pipeline
Chad Landmon, attorney and chair of Axinn’s Intellectual Property and FDA Practice Groups, discusses upcoming clinical trials on COVID-19 booster shots, the possibility of cancer vaccines, and the future of pharmaceuticals and FDA approvals.
Advertisement
Pharmacy Times spoke with Chad Landmon, attorney and chair of Axinn’s Intellectual Property and FDA Practice Groups, about key events in the FDA pipeline, such as Emergency Use Authorizations during COVID-19 and the future of narrowed approvals.
Landmon went into further detail on upcoming clinical trials on COVID-19 booster shots, the possibility of cancer vaccines, and the future of pharmaceuticals and FDA approvals.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Obinutuzumab-Bendamustine Produces High Response Rates in Chinese Patients With Indolent B-Cell Lymphomas
2
State Pharmacy Boards Must Step Up Against Illegal Retatrutide
3
Dosing, Monitoring, and Counseling: The Pharmacist's Role in TKI Therapy for Systemic Mastocytosis
4
New CKD Outcome Set Tells Pharmacists What to Measure
5





































































































